Z-drugs (zolpidem, zopiclone): when they help, when they don't, and why Slumbr only prescribes them once-off

Z-drugs — the short-acting sedative-hypnotics that include zolpidem and zopiclone — work. They work reliably, they work quickly, and they have a much better short-term safety profile than the older benzodiazepines they replaced. The clinical question is not whether they work; it is for how long, and at what cost. Used briefly, in the right patient, for the right indication, a z-drug can break a crisis pattern of insomnia and return a patient to a sustainable sleep architecture. Used chronically — beyond about 2 to 4 weeks — they slide into dependence, rebound insomnia, daytime grogginess, and increased fall risk. At Slumbr, z-drugs are prescribed once-off, as a 14-day course, only after a specialist consultation, and never on a subscription. Each repeat is a fresh clinical decision. This article is the why.

Are z-drugs the same as benzodiazepines? (Short answer: no, but it is complicated)

The z-drugs are a chemically distinct group from the benzodiazepines. The name "z-drugs" comes from the fact that the first three molecules in the class — zolpidem, zopiclone, and zaleplon — all start with Z. They are formally called non-benzodiazepine benzodiazepine-receptor agonists (NBBRAs).

Chemically:

• Benzodiazepines (diazepam, lorazepam, alprazolam) share a benzodiazepine ring structure.
• Z-drugs are structurally unrelated. Zolpidem is an imidazopyridine; zopiclone is a cyclopyrrolone.

Pharmacologically, however, they overlap. Both classes bind to the GABA-A receptor — the brain's primary inhibitory receptor — and both produce sedation through that pathway. Z-drugs are more selective for the α1 subunit (the subunit most associated with sedation), where benzodiazepines bind more broadly (α1, α2, α3, α5), which is why benzodiazepines also produce muscle relaxation, anxiolysis, and anticonvulsant effects in addition to sedation.

For sleep specifically, this matters because:

• Benzodiazepines prescribed for insomnia (such as flurazepam or temazepam internationally; less common in South Africa) carry a higher dependence and rebound risk than z-drugs, partly because of their broader receptor binding and partly because their half-lives tend to be longer.
• Z-drugs were developed in the 1980s–90s specifically as "cleaner" alternatives — shorter-acting, less daytime hangover, intended for sleep onset.

So: zolpidem and zopiclone are z-drugs, not benzodiazepines. They are often grouped together in prescribing guidelines because their clinical profile for short-term sleep use is similar, but the distinction is real and worth knowing.

What z-drugs do

In South Africa, zolpidem is registered under the brand name Stilnox® (Sanofi). Zopiclone is registered as Imovane® (Sanofi). The same molecules are also dispensed as generic equivalents under other names.

⚠ Brand-name clarification: Stilnox is zolpidem. Stilpane is a different medicine — a paracetamol + codeine + meprobamate combination used for pain — and is not a z-drug at all. The two brand names sound similar; if you have been told a medicine is "for sleep" please check the active ingredient on the package.

Z-drugs act on the GABA-A receptor (as above), producing sedation that arrives within 15–30 minutes, lasts 4–6 hours, and clears before morning at standard doses.

In healthy clinical use:

• Onset of action is fast — useful for sleep-onset insomnia where lying awake is the main problem.
• Half-life is short — zolpidem about 2.5 hours, zopiclone about 5 hours — so the morning grogginess that benzodiazepines were famous for is largely absent at standard doses in healthy adults.
• No deep sedation effect like the older drugs. Patients wake briefly during the night, do their normal things, return to sleep.

That clean profile is why the z-drugs displaced benzodiazepines for primary insomnia in most prescribing guidelines worldwide. They are the right answer in the right window.

Why the right window is so narrow

Two issues — both well-established in clinical literature — make chronic z-drug use the wrong answer for chronic insomnia.

1. Tolerance and dose escalation

After about two weeks of nightly use, the GABA-A receptor down-regulates. The same dose produces less sedation. The patient sleeps less well than they did at the start. The natural next step is a higher dose, which works briefly, until tolerance catches up again. Within a few months, many patients are on doses that started as "rescue" and are now baseline — and the sleep is no better than it was before treatment, sometimes worse.

2. Rebound insomnia

When a chronic z-drug user stops the drug — for any reason, even just a missed prescription — the body's sleep machinery, which has been suppressed by the GABA-A signalling, takes 1 to 3 weeks to reset. During that window, sleep is significantly worse than it was before treatment ever started. This is rebound insomnia, and it is the reason most people who try to stop z-drugs go back. The drug is now treating the problem the drug created.

These two patterns are why current sleep-medicine guidelines recommend z-drug use be time-limited from day one. The specific upper limit varies by guideline:

• UK NICE (TA77, 2004 — still current as of last review): the shortest period possible, up to a maximum of 4 weeks including any tapering.
• EMA / SAHPRA package inserts for zolpidem and zopiclone in South Africa: up to 4 weeks including any tapering.
• American Academy of Sleep Medicine 2017 guidelines: weak recommendation for short-term use; no fixed upper limit but emphasises ongoing risk–benefit assessment.

The Slumbr formulary policy is a 14-day course, which is more conservative than the upper limit of the package insert. This is a deliberate clinic-level position: most patients who would have benefited from a z-drug have benefited within two weeks, and the dependence and rebound risks rise meaningfully beyond that.

When a z-drug is the right answer

The right use case is short, defined, and indication-specific:

• A 7–14 day course to break a crisis pattern of acute sleep-onset insomnia, where the patient has lost the ability to fall asleep at all and the lack of any sleep is itself a clinical emergency. The z-drug gives the body two weeks of restored sleep architecture, after which the underlying maintaining factor (usually hyperarousal) can be addressed without the patient being too sleep-deprived to engage.
• A pre-defined intermittent use for a known stressor — a surgical recovery period, a major life event with a known short timeline. Two or three doses across a defined fortnight, then stop.
• As a brief adjunct during circadian re-timing — shift change, severe jet lag. Two or three doses to bridge the timing window while light therapy does the actual circadian work.

In all three cases the prescription is once-off, the duration is fixed in advance, and there is no automatic refill.

When a z-drug is the wrong answer

A short list of patterns where reaching for a z-drug is the clinical error:

• Chronic insomnia without a defined crisis. This is the most common misuse — a z-drug given as "treatment" when the patient has had insomnia for months. The right answer is CBT-I, then if that is not enough, a class that is not dependence-forming (a dual orexin receptor antagonist; for adults 55+, prolonged-release melatonin).
• Patients with a history of substance use disorder. Even brief use carries a relapse risk. Other classes exist.
• Adults over 65. Fall risk and confusion risk go up sharply. Other classes are safer.
• As a "what helps?" trial. The trial that works for a fortnight then fails is not informative — it tells you the patient responds to GABA sedation, which everyone does. It does not tell you what is driving the insomnia.

Why Slumbr only prescribes z-drugs once-off

Three reasons, in plain language:

1. Clinical evidence. The harm-to-benefit ratio inverts past 4 weeks. Subscription billing — even with good intent — creates the conditions for chronic use.
2. Regulatory. The South African Medicines Act treats z-drugs as Schedule 5 prescription medicines, with the 6-month repeat-prescription cap (Reg 22A(6)) and a clinical expectation of regular re-assessment.
3. The Slumbr position. A clinic that earns recurring revenue from a class of drugs evidence says should be used briefly has the wrong incentives. Setting the platform to make subscription impossible for these drugs is how we make the clinical rule structural rather than reliant on individual restraint.

The practical implication: if you have a z-drug prescription from Slumbr, you receive a 14-day supply once, dispensed by our in-house pharmacy. Fourteen days later you receive a follow-up message from the clinic asking whether the underlying pattern needs further consultation. Continuing requires a fresh prescription, which requires a fresh clinical decision.

What the rest of the prescription landscape looks like

For the chronic insomnia case where a z-drug is the wrong tool, Slumbr has a different set of classes available after a consultation:

• Dual orexin receptor antagonists (DORAs) — preferred class for hyperarousal insomnia and many sleep-maintenance presentations. Non-dependence-forming.
• Prolonged-release melatonin — first-line for chronic insomnia in adults aged 55 and over. Non-dependence-forming.
• Compounded low-dose doxepin — Slumbr's flagship for sleep-maintenance insomnia. Selective H1 antagonism, no dependence.
• Low-dose mirtazapine — considered only where a depression assessment has identified a mood disorder, in the context of an overall mental-health management plan.

You can read the per-phenotype detail on the treatments pages and the Sleep Pattern Assessment™ will route you to the right one.

What this is not

This article is general clinical information, not a diagnosis. If you are in crisis or experiencing thoughts of self-harm, please contact SADAG on 0800 567 567 (24/7) or your nearest emergency department. Slumbr Sleep Clinic does not provide emergency care.

If you are taking a z-drug now and would like a structured plan to come off it (or to continue it appropriately), book a specialist consultation. The taper is straightforward when it is done with clinical oversight and very difficult when it is not.

Reviewed by an HPCSA-registered specialist physician with sleep-medicine training. References on file. Last updated May 2026.